Peptide Protocols: How to Structure Dosing, Cycling, and Stacking

Getting the right peptide is only half the equation. How you use it — the dose, timing, cycle length, and whether you combine it with other peptides — determines whether you see meaningful results or waste your money. This is what peptide therapy practitioners mean when they talk about “protocols.”

A protocol isn’t just a dose on a label. It’s the full picture: when to inject, how long to run a cycle, when to take breaks, what to stack together, and how to adjust based on your response. The difference between a well-designed protocol and random peptide use is often the difference between results and disappointment. If you’re new to peptide therapy, this guide will give you the framework to understand what your provider prescribes — or to ask better questions if something doesn’t add up.

Key Takeaways

• Most peptide protocols run 4-12 weeks on, followed by 2-8 weeks off — continuous indefinite use is not recommended for most compounded peptides due to limited long-term safety data [1]
• Timing matters significantly — growth hormone-releasing peptides should be taken on an empty stomach (ideally before bed), while BPC-157 is typically taken near the injury site twice daily [2]
• Stacking peptides can enhance results but also increases complexity and cost — common stacks include BPC-157 + TB-500 for recovery and CJC-1295 + Ipamorelin for GH release [3]
• FDA-approved peptides (semaglutide, tirzepatide) follow standardized titration schedules, while compounded peptide protocols vary significantly between providers

Table of Contents

1. What Is a Peptide Protocol?
2. Dosing Fundamentals
3. Cycling: Why Breaks Matter
4. Common Peptide Protocols by Goal
5. Stacking Peptides
6. Timing and Administration
7. Reconstitution and Storage
8. Adjusting Your Protocol
9. Side Effects and When to Stop
10. Cost of Common Protocols
11. FAQ
12. Sources

What Is a Peptide Protocol?

A peptide protocol is a structured plan that specifies five things: which peptide(s) to use, how much to take per dose, how often to dose, how long to continue, and when to stop or cycle off.

This matters because peptides aren’t like vitamins you take daily forever. Most interact with specific receptor systems that can become desensitized with continuous use. Growth hormone secretagogues, for example, may lose effectiveness if used without breaks — the pituitary gland downregulates its response over time [4]. Recovery peptides like BPC-157 are typically used for a defined treatment window, not ongoing maintenance.

The distinction between FDA-approved and compounded peptide protocols is worth noting upfront. FDA-approved peptides (semaglutide, tirzepatide, tesamorelin) come with manufacturer-specified dosing schedules validated through clinical trials. Compounded peptides (BPC-157, CJC-1295/Ipamorelin, GHK-Cu, TB-500) rely on provider experience, animal study extrapolations, and clinical observation rather than phase 3 trial data.

Dosing Fundamentals

Peptide doses are measured in micrograms (mcg) or milligrams (mg), and the right dose depends on the specific peptide, your body weight, your goals, and your response.

Weight-Based vs. Fixed Dosing

FDA-approved GLP-1 agonists use fixed titration schedules. Semaglutide starts at 0.25 mg weekly and increases to 2.4 mg over 16-20 weeks, regardless of body weight [5]. This approach is backed by large clinical trials.

Compounded peptides typically use weight-adjusted dosing or fixed ranges:

• BPC-157: 200-500 mcg per dose, 1-2x daily. Some practitioners use 2-3 mcg/kg body weight as a starting point [6]
• CJC-1295/Ipamorelin: 100-300 mcg of each peptide, typically once daily at bedtime [7]
• TB-500: 2-2.5 mg twice weekly during loading, then 2-2.5 mg weekly for maintenance [8]
• GHK-Cu: 1-2 mg daily via subcutaneous injection, or topical application at 1-3% concentration [9]

Starting Low

The standard approach: start at the low end of the dosing range and increase based on response and tolerability. This is especially true for GLP-1 agonists, where jumping to high doses causes significant nausea in most people, and for growth hormone-releasing peptides, where excessive GH stimulation causes water retention and joint pain.

Cycling: Why Breaks Matter

Cycling means alternating periods of use (“on” cycles) with periods of rest (“off” cycles). Most peptide practitioners recommend cycling for three reasons:

Receptor sensitivity. Continuous stimulation of the same receptor pathway leads to downregulation. For growth hormone secretagogues, this means the pituitary becomes less responsive to the peptide signal over time. Taking breaks allows receptors to resensitize [4].

Safety. Long-term continuous use data simply doesn’t exist for most compounded peptides. Cycling introduces built-in safety margins.

Cost. Peptide therapy isn’t cheap. Cycling reduces annual spend by 30-50% compared to year-round use.

Standard Cycling Schedules

Peptide	On Cycle	Off Cycle	Notes
BPC-157	4-8 weeks	2-4 weeks	Goal-driven — stop when healing is achieved
CJC-1295/Ipamorelin	8-12 weeks	4-8 weeks	Some use 5 days on / 2 off within the cycle
TB-500	4-6 weeks loading, then maintenance	4 weeks between full cycles	Loading phase is higher dose
GHK-Cu	8-12 weeks	4 weeks	Topical can often be used longer
Semaglutide	Ongoing (FDA protocol)	Not cycled	Continuous use per prescribing info
Tirzepatide	Ongoing (FDA protocol)	Not cycled	Continuous use per prescribing info

Note the difference: FDA-approved GLP-1 drugs are designed for continuous use. Compounded peptides are not — or at least, we don’t have the data to support indefinite use.

Some practitioners use a “5 on / 2 off” micro-cycling approach within longer cycles, taking peptides Monday through Friday with weekends off. The rationale is maintaining receptor sensitivity, though published evidence supporting this specific pattern is limited [10].

Common Peptide Protocols by Goal

Recovery and Injury Healing

The BPC-157 + TB-500 combination is the most popular recovery protocol. Often called the “Wolverine Stack,” it pairs BPC-157’s tendon and ligament healing properties with TB-500’s broader tissue repair and anti-inflammatory effects.

Typical protocol:

• BPC-157: 250-500 mcg subcutaneously, twice daily (morning and evening), injected as close to the injury site as practical
• TB-500: 2.5 mg subcutaneously, twice weekly for weeks 1-4 (loading), then once weekly for weeks 5-8
• Duration: 6-8 weeks
• Break: 4 weeks minimum before repeating

Growth Hormone Optimization

The CJC-1295 + Ipamorelin stack is the standard growth hormone protocol. CJC-1295 extends the half-life of GH release while Ipamorelin triggers the pulse, creating a more physiological pattern of GH secretion than either peptide alone.

Typical protocol:

• CJC-1295 (no DAC): 100-200 mcg subcutaneously at bedtime
• Ipamorelin: 100-200 mcg subcutaneously at bedtime (same injection or separate)
• Timing: 30+ minutes after last meal, ideally before sleep
• Duration: 8-12 weeks on, 4-8 weeks off
• Some add a second dose post-workout on training days

Weight Management

GLP-1 protocols follow manufacturer guidelines:

Semaglutide (Wegovy):

• Month 1: 0.25 mg weekly
• Month 2: 0.5 mg weekly
• Month 3: 1.0 mg weekly
• Month 4: 1.7 mg weekly
• Month 5+: 2.4 mg weekly (maintenance)

Tirzepatide (Zepbound):

• Weeks 1-4: 2.5 mg weekly
• Weeks 5-8: 5 mg weekly
• Escalation continues in 2.5 mg increments every 4 weeks to max 15 mg weekly

These are not cycled. They’re taken continuously, and discontinuation often leads to weight regain — the STEP 4 trial showed participants regained about two-thirds of lost weight within a year of stopping semaglutide [11].

Skin and Anti-Aging

GHK-Cu-based protocols target collagen synthesis and skin quality:

Typical protocol:

• GHK-Cu: 1-2 mg subcutaneously daily for 8-12 weeks
• Often combined with topical GHK-Cu serum (1-3% concentration) applied to target areas
• Can be stacked with CJC-1295/Ipamorelin for synergistic GH-driven collagen stimulation
• Break: 4 weeks between injectable cycles

Stacking Peptides

Stacking means using two or more peptides simultaneously to target complementary pathways. Done right, stacking can amplify results. Done wrong, it adds cost and complexity without clear benefit.

Stacks That Make Pharmacological Sense

BPC-157 + TB-500: Different mechanisms of tissue repair. BPC-157 works through nitric oxide and growth factor modulation; TB-500 promotes cell migration and reduces inflammation. Combined, they address healing from multiple angles [12].

CJC-1295 + Ipamorelin: Complementary GH-releasing mechanisms. CJC-1295 (a GHRH analog) tells the pituitary to release GH; Ipamorelin (a ghrelin mimetic) amplifies the signal through a separate receptor. The combination produces a stronger, more natural GH pulse than either alone [7].

GLP-1 + GH-releasing peptides: Some providers prescribe semaglutide alongside CJC-1295/Ipamorelin to counteract the lean mass loss that GLP-1 drugs can cause. The logic is sound — GH supports lean mass — but clinical data on this specific combination is lacking.

Stacks to Approach With Caution

Multiple GH-releasing peptides: Stacking CJC-1295/Ipamorelin with sermorelin or tesamorelin creates overlapping mechanisms without clear additive benefit, while increasing the risk of excessive GH stimulation.

Peptides with unknown interactions: The more compounds you add, the less predictable the outcome. Most peptide interaction data comes from clinical observation, not controlled studies.

Timing and Administration

When and how you take peptides significantly affects their efficacy.

Growth Hormone Peptides

Take on an empty stomach — insulin and elevated blood sugar blunt GH release. The ideal window is either:

• Before bed (at least 2 hours after eating): Amplifies the natural nocturnal GH pulse
• Morning fasted: Practical alternative, though nighttime dosing may be slightly more effective for GH release [13]

Some protocols include a second dose post-workout on training days, leveraging the exercise-induced GH response.

BPC-157

Take twice daily (morning and evening) for consistent tissue-level exposure. Inject subcutaneously near the injury site when possible — local administration may enhance local healing effects, though systemic effects occur regardless of injection site [6].

GLP-1 Agonists

Once weekly, same day each week. Can be taken at any time, with or without food. Most people choose a day when mild nausea won’t interfere with important activities.

Injection Technique

Subcutaneous injection into the abdominal fat pad is the standard for most peptides. Rotate injection sites to prevent lipohypertrophy (fatty lumps). Use insulin syringes (29-31 gauge) for comfort. For potential side effects related to injection technique and other aspects of peptide use, see our dedicated guide.

Reconstitution and Storage

Most compounded peptides arrive as lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before use. This is a step many beginners find intimidating, but it’s straightforward once you’ve done it.

Our complete reconstitution guide walks through the process step-by-step, including the math for calculating your dose based on how much water you add. The short version:

• Add bacteriostatic water slowly, aiming it at the vial wall (not directly on the powder)
• Swirl gently — never shake
• Reconstituted peptides must be refrigerated at 2-8°C (36-46°F)
• Most reconstituted peptides remain stable for 3-4 weeks refrigerated
• Never freeze reconstituted peptides
• Lyophilized (unreconstituted) peptides can be stored frozen for months

Adjusting Your Protocol

No protocol is set-and-forget. Adjustments should be based on:

Symptom response: Are you seeing the expected effects? BPC-157 users typically notice reduced pain and improved mobility within 1-3 weeks. CJC-1295/Ipamorelin users often report improved sleep within the first week, with body composition changes appearing over 4-8 weeks [2].

Side effects: Water retention, joint stiffness, or numbness/tingling with GH peptides suggests the dose may be too high. Dose reduction by 25-50% usually resolves these. Persistent nausea on GLP-1 agonists may warrant slowing the titration schedule.

Lab work: For GH-releasing peptide protocols, IGF-1 levels provide an objective measure of response. A meaningful increase (50-100+ ng/mL above baseline) suggests the peptide is working. No change after 4-6 weeks suggests the dose needs adjustment or the product quality may be an issue [14].

Body weight changes: For GLP-1 protocols, weight loss of 1-2% body weight per month is a healthy pace. Faster loss may indicate the dose is too aggressive; slower may indicate a plateau requiring dose escalation.

Side Effects and When to Stop

Every peptide protocol should include clear stopping criteria.

Stop and contact your provider if you experience:

• Severe or persistent nausea/vomiting (GLP-1 agonists)
• Significant edema or carpal tunnel symptoms (GH peptides)
• Signs of allergic reaction (rash, difficulty breathing)
• Unexplained pain or lumps at injection sites
• New or worsening headaches

Common, manageable side effects:

• Mild nausea during GLP-1 titration (usually resolves in 1-2 weeks per dose level)
• Temporary water retention when starting GH peptides (often resolves within 2 weeks)
• Injection site redness or irritation (improve technique, rotate sites)
• Fatigue or vivid dreams with bedtime GH peptide dosing (typically transient)

Cost of Common Protocols

Protocols vary significantly in cost. Here’s what typical 8-week cycles run:

Protocol	Monthly Cost	8-Week Total
BPC-157 alone (500 mcg/day)	$150-250	$300-500
BPC-157 + TB-500	$250-450	$500-900
CJC-1295/Ipamorelin	$200-350	$400-700
GHK-Cu injectable	$150-300	$300-600
Semaglutide (compounded)	$200-400	$400-800
Semaglutide (brand Wegovy)	$800-1,500	$1,600-3,000

These are peptide costs only — add provider consultation fees ($150-350 initial, $75-200 follow-up) and supplies (syringes, bacteriostatic water, ~$20-30/month). For a full breakdown, see our peptide therapy cost guide.

FAQ

How long should I cycle peptides?▼

It depends on the peptide. BPC-157 and TB-500 are typically run for 4-8 weeks with 2-4 weeks off. CJC-1295/Ipamorelin cycles are usually 8-12 weeks with 4-8 weeks off. FDA-approved GLP-1 agonists are taken continuously without cycling. Your provider should specify cycle length based on your goals and response.

Can I take multiple peptides at the same time?▼

Yes, stacking is common and often recommended for complementary goals. BPC-157 + TB-500 for recovery and CJC-1295 + Ipamorelin for GH release are well-established combinations. The key is stacking peptides that work through different mechanisms rather than duplicating the same pathway.

What time of day should I take peptides?▼

Growth hormone peptides (CJC-1295, Ipamorelin, sermorelin) work best taken on an empty stomach before bed. BPC-157 is typically split into two doses (morning and evening). GLP-1 agonists are once-weekly at any time. Always follow your provider’s specific instructions.

How do I know if my peptide protocol is working?▼

Expected timelines: BPC-157 — pain reduction within 1-3 weeks. CJC-1295/Ipamorelin — better sleep within 1-2 weeks, body composition changes over 4-8 weeks. Semaglutide — appetite suppression within days, measurable weight loss within 4 weeks. If you see no response after 4-6 weeks, discuss adjustments with your provider.

Do I need blood work during a peptide protocol?▼

For GH-releasing peptide protocols, baseline and 6-week IGF-1 levels help confirm the peptides are working. For GLP-1 protocols, monitoring fasting glucose, HbA1c, and lipid panels is standard. BPC-157 and TB-500 protocols don’t have standard monitoring labs, though a basic metabolic panel at baseline is reasonable.

Sources

1. Rupa Health. BPC 157: Science-Backed Uses, Benefits, Dosage, and Safety. 2025. https://www.rupahealth.com/post/bpc-157-science-backed-uses-benefits-dosage-and-safety

2. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. doi:10.1016/j.sxmr.2017.02.004

3. Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. doi:10.2174/1570159X13666160502153022

4. Veldhuis JD, et al. Neuroendocrine control of growth hormone secretion. Growth Horm IGF Res. 2006;16(Suppl A):S17-S24. doi:10.1016/j.ghir.2006.03.012

5. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183

6. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157-therapy and the operative procedures. Curr Pharm Des. 2018;24(18):1930-1935. doi:10.2174/1381612824666180515124856

7. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536

8. Crockford D, et al. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-189. doi:10.1111/j.1749-6632.2010.05492.x

9. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108

10. Balanced Aesthetics MedSpa. Peptide Therapy & Cycling Protocols. 2025. https://balancedaestheticsmedspa.com/peptide-cycling-why-smart-scheduling-matters-more-than-you-think/

11. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224

12. Vukojevic J, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. doi:10.4103/1673-5374.320969

13. Van Cauter E, et al. Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men. JAMA. 2000;284(7):861-868. doi:10.1001/jama.284.7.861

14. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611. doi:10.7326/0003-4819-149-9-200811040-00003

15. U.S. Food and Drug Administration. Bulk Drug Substances That Are Nominated for Evaluation. FDA.gov. Updated 2024.